Basilea wins USD 5.4 million BARDA grant for ceftibuten-ledaborbactam antibiotic development
Reuters2026/08/05 05:15- Basilea won USD 5.4 million in additional BARDA funding to advance oral antibiotic ceftibuten-ledaborbactam for complicated urinary tract infections.
- Total BARDA funding awarded to Basilea rose to USD 30.8 million; the contract allows up to USD 172 million in non-dilutive support.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. consumer confidence index falls more than expected, inflation expectations rise, Republican satisfaction hits lowest level during Trump's term
At the beginning of September, the consumer confidence index dropped from 51.7 in August to 47.8. Consumers' inflation expectations for the next year jumped from 4% to 4.6%. Most consumers anticipate that the Federal Reserve will raise interest rates within the next year, marking the first time since 2023. Only 35% of Republican respondents believe the government is performing well in economic management, the lowest reading since Trump's return to the White House last year.
Mary Chia CFO Su Jun Ming to retire as executive director, step down Sept. 28, 2026
Marcus & Millichap’s IPA brokers USD 83 million sale of two Oregon multifamily properties
Crypto prices
More
